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Abstract
Triple negative breast cancer (TNBC) is a heterogeneous disease that has a poor prognosis
and limited treatment options. Chemokine receptor interactions are important modulators of
breast cancer metastasis; however, it is now recognized that quantitative surface expres-
sion of one important chemokine receptor, CXCR4, may not directly correlate with metasta-
sis and that its functional activity in breast cancer may better inform tumor pathogenicity. G
protein coupled receptor kinase 3 (GRK3) is a negative regulator of CXCR4 activity, and we
show that GRK expression correlates with tumorigenicity, molecular subtype, and meta-
static potential in human tumor microarray analysis. Using established human breast can-
cer cell lines and an immunocompetent in vivomouse model, we further demonstrate that
alterations in GRK3 expression levels in tumor cells directly affect migration and invasion in
vitro and the establishment of distant metastasis in vivo. The effects of GRK3 modulation
appear to be specific to chemokine-mediated migration behaviors without influencing tumor
cell proliferation or survival. These data demonstrate that GRK3 dysregulation may play an
important part in TNBC metastasis.
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1. Introduction
Breast cancer is the most prevalent and deadliest form of cancer in women world-wide and tri-
ple negative breast cancers (TNBC) account for approximately 15–20% of all breast cancers [1,
2]. Triple negative breast cancer is a heterogeneous disease defined by negative expression for
estrogen receptor (ER) and progesterone receptor (PR), and normal (low) expression levels of
Her2. Recent molecular characterization has identified five breast cancer subtypes (luminal A,
luminal B, HER2-enriched, basal-like, and claudin-low). Approximately 90% of TNBC tumors
are basal-like or claudin-low subtypes, with 70% of basal-like being identified as triple-negative
and 80% of claudin-low identified as ER-/-, PR-/-, Her2-/-[3]. Triple negative breast cancers
are often highly invasive, metastatic, possess a high risk for relapse, and carry a poor prognosis
[4, 5], and the different genetic subtypes can be associated with organ-specific metastasis and
relapse [6]. As hormone receptor antagonism is less applicable in TNBC, alternative targets
are being investigated to better understand pathogenesis and to design therapeutics for these
patients.
The G protein coupled receptors (GPCR), such as CXCR4, and its chemokine ligand
CXCL12, have been identified as important regulators of metastasis and tumor behavior in
breast cancer [7–9]. CXCL12 is highly expressed at common sites of breast cancer metastasis,
such as the lymph nodes, liver, bone marrow, and lungs [7], and CXCR4 on tumor cells is criti-
cal for growth and migration [9]. While CXCR4 expression on tumor cells is important for
metastasis, work published by Holland, et al. has emphasized that functional activation and sig-
naling of CXCR4 in breast cancer cells may be more predictive of malignant potential than
quantitative surface expression [10]. Thus, the intracellular signaling responses of chemokine
receptor activation are of critical importance to metastasis and the malignant phenotype.
G protein coupled receptor kinases (GRKs) are signaling regulators of agonist-activated che-
mokine receptors. Agonist activation leads to phosphorylation of the receptor tail by GRK, the
recruitment of beta-arrestin, uncoupling of heterotrimeric G proteins, and ultimately desensiti-
zation and internalization of the receptor [11, 12]. Thus, GRKs serve as negative regulators of
GPCRs. Reduced expression of GRK3, 4, and 6 have previously been reported to increase
tumor malignancy of glioblastoma, ovarian tumors, and medulloblastoma, respectively,
through dysregulation of GPCR signaling [13–15]. In the glioblastoma model specifically,
decreased GRK3 expression resulted in abnormally sustained CXCR4 signaling and enhanced
tumor growth [14]. Further, GRK3 has been shown to regulate CXCL12-mediated cellular
migration and CXCR4 internalization and MAPK signaling in human and mouse models of
immune deficiency and inflammation [16, 17].
Given the aforementioned importance of GRK3 in CXCR4 signaling regulation and the role
of CXCL12 and CXCR4 in malignancy [9, 18, 19], we hypothesized that GRK3 regulation of
CXCL12/CXCR4, as well as potentially other chemokine receptor interactions, may further dis-
tinguish differences in metastatic potential and prognosis in patient subsets within TNBC. To
predict the relevance of GRK3 in human breast cancer subtypes, we analyzed TCGA and publi-
cally available microarray data for GRK correlations with molecular subset distinction and
metastasis. To test the potential mechanism of GRK3 regulation of CXCR4 in disease, human
TNBC cell lines MDA-MB-231 (highly invasive) and MDA-MB-468 (weakly invasive) [20]
were examined for GRK3 and CXCR4 expression and for functional migration phenotypes
when GRK3 expression was altered. To test the effects of GRK3 on tumor growth and metasta-
sis in vivo, we used GRK3-deficient mammary tumor cells derived from Balb/c (66cl4-luc) as a
representative TNBC model system in an immunocompetent mouse [21]. Our studies show
that GRK3 is decreased in specific molecular subsets of TNBC with increased metastasis in
humans and that GRK3 expression can predict the functional phenotype of migration and
GRK3 Regulates Breast Cancer Metastasis
PLOS ONE | DOI:10.1371/journal.pone.0152856 April 6, 2016 2 / 23
P30 CA016086 Cancer Center Core Support Grant to
the UNC Lineberger Comprehensive Cancer Center.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
invasion in both in vitro and in vivomodel systems. Therefore, defining the relative expression
of GRK3 in relationship to chemokine receptors like CXCR4 in TNBC may provide prognostic
information for the aggressiveness of tumors and help discriminate patient subsets with the
greatest potential for metastasis beyond their chemokine receptor surface expression alone.
2. Materials and Methods
2.1. Human breast cancer genetic analysis
The TCGA database was analyzed, as well as public microarray datasets, as previously
described [6]. Specifically, these microarrays sets are deposited in the Gene Expression Omni-
bus with the accession numbers GSE26338, GSE2034, GSE12276, and GSE2603. Dataset
NKI295 was published prior to the adoption of GEO and can be found separately (http://ccb.
nki.nl/data/). The data was combined using Distance Weighted Discrimination [22] to remove
the systematic biases of different microarray sets and standardized to zero mean and unit vari-
ances prior to other analyses. Samples in the normalized data were assigned to the five subtypes
(luminal A, luminal B, Her2-enriched, basal-like, and normal) using the PAM50 classifier [23].
Assignment of claudin-low was performed according to the protocol described in Prat et al.[3]
Testing for differential expression of the candidate genes associated with subtype was per-
formed using ANOVA. Survival analysis was performed by grouping expression levels into
tertiles, then testing for association with metastasis free survival using the log rank test and
visualized with Kaplan Meier plots.
2.2. Mice and cell lines
In vivo experiments were performed in Balb/c mice. All animals were cared for under standard
Institutional Animal Care and Use Committee (IACUC)-approved protocols in the Associa-
tion for Assessment and Accreditation of Laboratory Animal Care-accredited vivarium at
the University of North Carolina. Luciferase-tagged murine breast cancer line 66cl4-luc (gener-
ated by Dr. G. Sahagian) [24] and human breast cancer lines MDA-MB-468, MDA-MB-453,
MDA-MB-231, DU4475, MCF-7, BT-474, SK-BR3, Hs578T, and ZR-75-1 were obtained from
the University of North Carolina Lineberger Cancer Center Tissue Culture Facility (TCF) and
maintained according to ATCC culture recommendations. Cell lines with stable lentiviral-
mediated expression of GRK3-knockdown shRNA or plasmid-mediated overexpression con-
structs were cultured in medium with the addition of selection antibiotics puromycin and/or
gentamicin at concentrations determined empirically by kill curve assays.
2.3. Lentiviral shRNA-mediated GRK3 silencing
Five target shRNAs were obtained for both human and mouse GRK3, which were cloned into
pLKO.1.-CMV (Sigma, St. Louis, MO). Target and non-target vectors were packaged into lenti-
viral particles by Sigma or by the UNC Lenti-shRNA Core Facility. Each of these was transduced
into the appropriate human (MDA-MB-468) or mouse (66cl4-luc) breast cancer lines and
selected by antibiotic resistance. These clones were screened via quantitative real-time PCR
(qRT-PCR) for GRK3 expression and confirmed with immunoprecipitation protein blotting (S1
and S2 Figs). CXCR4 surface protein expression was also tested by flow cytometry and confirmed
to be unaffected (S3 Fig). The target sequence producing the greatest GRK3-specific knockdown
with the fewest off-target effects (judged by lack of effect on housekeeping genes IDUA, 18S,
CXCR4, CXCR7 and GRK2—which has the closest sequence homology to GRK3) was selected
for use in further assays: human ADRBK2, TRCN0000002034, sequence 5'-CCGG-CAGTA
AATGCAGACACAGATA-CTCGAG-TATCTGTGTCTGCATTTACTG-TTTTT-3'; mouse
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ADRBK2, TRCN0000022703, sequence, 5’-CCGG-GCAGCATGTGTACTTACGGAA-CTCGAG-
TTCCGTAAGTACACATGCTGC-TTTTT-3’.
2.4. Overexpression of GRK3
MDA-MB-231 cells were transiently transfected with GRK3 or empty control plasmid
(pcDNA3.1 mCherry) using Lipofectamine LTX with Plus Reagent (Life Technologies,
Grand Island, NY) per manufacturer instructions. Following 20 hours of culture with plas-
mid, cells were washed and used after 2-24hr rest in complete media or were serum-starved,
where appropriate, prior to assay. Transient transfection efficiency was routinely 30–40%
determined by microscopy for mCherry expression. GRK3 overexpression was confirmed by
Western blot (S2 Fig).
2.5. Quantitative Real Time PCR
Cells were grown in appropriate culture media to approximately 75% confluence. Total RNA
was prepared using a Qiagen RNeasy kit and cDNA synthesized with Superscript II reverse
transcriptase (Invitrogen) followed by qRT-PCR. Fold differences in expression were calculated
using the 2-ΔCt method compared to housekeeping gene IDUA [17]. Transcript copy number
was based on the standard curve method [25]. Human primers for qRT- PCR are listed as 5’to
3’ sequence as follows: Human GRK2 forward ACTTCAGCGTGCATCGCAT, GRK2 reverse
GCTTTTTGTCCAGGCACTTCAT, GRK3 forward AAGCCTTCGAGGTGACATTTTT, GRK3
reverse GCAACCATAAACTTCCCCGAATC, IDUA forward CTCGGGCCACTTCACTGAC, IDUA
reverse CAGTCCGTACCTACCGATGTAT, CXCR7 forward TGCATCTCTTCGACTACTCAGA,
CXCR7 reverse GGCATGTTGGGACACATCAC, CXCR4 forward CTCACTGACGTTGGCAAAGA,
and CXCR4 reverse AGGAAGCTGTTGGCTGAAAA.
2.6. CXCR4 internalization assay
According to previously published protocols [17], transiently transfected control and GRK3-
overexpressed MDA-MB-231 cells were treated for the indicated times with 100nM CXCL12
at 37°C. After treatment, cells were washed twice with ice-cold PBS/0.1% BSA and CXCR4 sur-
face expression was analyzed via flow cytometry using anti-CXCR4 PE antibody, Clone 2B11
(eBioscience, San Diego, CA).
2.7 Tango assay of β-arrestin mobilization
Recruitment of β-arrestin to agonist-stimulated receptors was measured using a Tango assay as
previously reported [26, 27]. HTLA cells, a derivative of HEK293 cells, were transfected with
either a CXCR4 D2V2-TCS-tTA or CXCR3 D2V2-TCS-tTA receptor construct that both
lacked the V2 tail [26, 27]. For GRK3 over-expression, a GRK3 pcMyc_LIC plasmid was used.
In addition, either yellow-fluorescent protein (YFP) or pcMyc_LIC empty-vector was used as a
negative control and YFP was used as a transfection control. Briefly, HTLA cells were tran-
siently transfected with 3 μg of receptor and 3 μg of either empty-vector control or GRK3 via
calcium-phosphate precipitation in a 10 cm plate. Transfection efficiency was determined by
YFP epifluorescence detection to be consistently>70%. Cells were plated in a 384-well plate
(Greiner, 25,000 cells/well, 40 μL/well) in DMEM + 1% dialyzed FBS for an additional 24
hours. Cells were then serum starved for 2–4 hours in DMEM (no supplements) and followed
by stimulation with human CXCL12 or human CXCL11 at indicated concentrations (highest
concentration of 1 μM). After 18–24 hours, the medium was replaced with 1x BriteGlo reagent
(Promega, Madison, WI, USA). Luminescence was measured on the Promega Glomax
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Multi + Detection System (0.5 sec/ well). Background data for each independent run was sub-
tracted and data was normalized by setting 0% and 100% as the readout for the lowest and
highest concentration of the control condition, respectively. A one-tailed Student’s t-test was
used for statistical analysis at each concentration tested.
2.8. Chemotaxis and Chemoinvasion
Chemotaxis was performed using BD Fluoroblok 96-well chambers according to the manufac-
turer’s suggestions with the indicated concentrations of CXCL12 (R&D Systems, Minneapolis,
MN) in the lower chamber. Non-targeted controls and GRK3-deficient cells were added to the
upper chamber in 50 μl at a concentration of 2 x 106/ml. Kinetic migration curve data was col-
lected every 2 or 4 minutes and was tested for significance by a linear regression analysis (See
2.13 Statistics). Chemoinvasion of human breast cancer cells was performed using BDMatrigel
96-well chemoinvasion chambers according to manufacturer instructions. Due to reports of
the low invasive capacity of 66cl4 mammary tumor cells [28], chemoinvasion for this TNBC
cell line was performed at a lower matrix concentration using the Cultrex 96-well BME Cell
Invasion Assay in accordance with manufacturer instructions (Trevigen, Gaithersburg, MD).
2.9. CXCL12 ELISA
66cl4-luc mammary tumor cells were plated at the indicated cell number per well. Supernatants
were collected at 48 hours and analyzed by sandwich ELISA with a Mouse CXCL12/SDF-1
DuoSet (R&D Systems, Minneapolis, MN).
2.10. Proliferation assay
Cell proliferation was determined using CCK-8, Cell Counting Kit 8 (Dojindo, Rockville, MD),
according to manufacturer protocol. Briefly, CCK-8 reagent was added at indicated times to
cells plated at 5000 cells per well in a 96-well plate and analyzed using a standard plate reader.
2.11. Apoptosis assay
Assessment of anoikis was performed as previously described [29]. Briefly, 1–2 x 106 66cl4-luc
GRK3-deficient and 66cl4-luc control cells were cultured either on tissue-culture treated
6-well plates or those pre-coated with poly 2-hydroxyethyl methacrylate (poly-HEMA) (Sigma,
St. Louis, MO) for 20 hours at 37°C in a 5% CO2 incubator. Cells were harvested, washed, and
assayed for apoptosis using FITC-annexin V and propidium iodide (PI) staining (Trevigen,
Gaithersburg, MD). Samples were analyzed by flow cytometry.
2.12. In vivo tumor progression
Syngeneic, luciferase-tagged mouse breast cancer line 66cl4-luc was transformed with
GRK3-specific knockdown shRNA or control virus. Efficacy and specificity of GRK3 knock-
down was confirmed as detailed above. This cell line, as well as a control transduced with a
non-target shRNA, was surgically implanted into the mammary fat pad in 6 week-old female
BALB/c mice. Mice were serially monitored for tumor progression via visualization of the lucif-
erase-tagged tumor cells on an IVIS imaging platform (Caliper Life Sciences, MA), and were
sacrificed at 6 weeks post-implantation. Xenogen software was used to quantify primary and
metastatic tumor burden as average radiance (p/s/cm2/sr).
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2.13. Statistics
Kinetic migration curve data was compared by analysis of covariance (ANCOVA) linear
regression model. See Supplemental Information for full description. Statistical significance for
all other assays was determined by two-tailed t-test using GraphPad Prism version 6.00 for
Windows unless otherwise noted.
3. Results
3.1. Decreased GRK3 expression correlates with basal-type breast
cancer and liver metastasis in humans
To determine whether GRK expression was different between the molecular breast cancer sub-
types, genomic data from the TCGA database and publicly-available databases were analyzed
as previously described by Harrell, et al [6]. Analysis of public human breast cancer microarray
data shows that only GRK3 and GRK5 isotypes are expressed at statistically significant lower
levels in tumor cells compared to normal breast tissue (Fig 1A). Also from this analysis, Fig 1B
shows that GRK3 expression is lowest in the basal subtype (red box), while GRK5 was
decreased most in luminal subtypes (blue boxes). Although increased CXCR4 expression can
indicate increased metastatic potential in some instances [30, 31], differential expression of
CXCR4 was not significant across these combined datasets (Fig 1A). When claudin-low and
basal-type samples were grouped by GRK3 expression level (Fig 1C), analysis of the human
breast cancer data showed significant correlation of tumors expressing medium (black line)
and low levels (red line) of GRK3 to liver metastasis and a similar trend toward lymph node
metastasis, while tumors expressing high levels of GRK3 (green line) remained nearly metasta-
sis-free. Similar results were seen in the analysis of the TCGA database (Fig 1D) where GRK3
and GRK5 again showed lower expression levels in tumor cells compared to normal breast tis-
sue. Using this data, CXCR4 expression was shown to significantly increase in tumor cells com-
pared to normal tissue as previously believed [30, 31]. Fig 1E shows TCGA analysis comparing
breast cancer subtypes and confirms that CXCR4 expression is highest and GRK3 is lowest in
basal types, though these trends are seen in all the tumor subtypes to some degree. GRK5
expression is again shown to be downregulated the most in luminal B subtype, but could also
be important in other types, including basal tumors. Taken together, there is potential clinical
significance for decreased GRK3 expression in human basal breast cancer that could indicate
metastatic potential.
3.2. GRK3 regulates CXCR4 function and the metastatic phenotype in
human TNBC cell lines
Studies by Holland and colleagues have shown that CXCR4 signaling activation, as opposed to
the quantitative surface expression of CXCR4, most strongly affects metastatic behavior of
human breast cancer cells [10], and this is additionally suggested by database analysis from Fig
1A. Because GRK3 negatively regulates CXCR4 function [14, 16, 17], we hypothesized that the
presence of low GRK3 would be less effective at desensitizing CXCR4 signaling and would cre-
ate a more aggressive metastatic phenotype. To explore this, qRT-PCR was used to establish
association relationships between CXCR4 and GRK3mRNA transcript levels (Fig 2) with
known invasiveness of human TNBC cell lines [32, 33]. Though mRNA levels do not always
correlate with protein levels, the qRT-PCR approach was undertaken as a potentially reliable
prognostic assay, given the low intracellular endogenous protein expression of GRK3 and sub-
stantial cross-reactivity of antibody reagents with homologous GRK2, which is expressed in
larger amounts (as shown in S1 Fig). The highly invasive breast cancer lines MDA-MB-231
GRK3 Regulates Breast Cancer Metastasis
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and DU4475 had CXCR4:GRK3mRNA expression ratios of 7:1 and 6:1, respectively. Moder-
ately invasive lines had ratios of 2:1 to 1:1 and the weakly invasive breast cancer lines had a
CXCR4:GRK3 expression ratio less than 1 (Fig 2). Because the GPCR CXCR7 also binds to
CXCL12 and has been shown to have a potential a role in tumor growth and metastasis [34],
we also compared CXCR7:GRK3 expression ratios, but they did not correlate with invasive phe-
notype (S4 Fig).
To further define the regulatory role of GRK3 in CXCL12/CXCR4-mediated function, the
CXCR4:GRK3 ratios were experimentally altered by either GRK3 overexpression or lentiviral
transduced GRK3 shRNA knockdown in the human cell lines MDA-MB-231 and MDA-MB-
468, respectively. These two TNBC cell lines were chosen as comparators for being most
different in intrinsic CXCR4:GRK3 ratio (Fig 2) and invasive potential [32, 33, 35]. GRK3 was
transiently overexpressed in the highly invasive MDA-MB-231 breast cancer cell line and
Fig 1. Genetic analysis of human breast cancer gene expression data associate GRK3 with tumor, basal subtype, andmetastasis.Microarray
datasets previously analyzed in Harrell, et al., were reanalyzed to (A) compareCXCR4 andGRK expression levels between normal breast tissue and tumor
tissue, (B) determine the significance of CXCR4,GRK3, andGRK5 expression levels in human breast cancer subtypes, and (C) examine the association of
GRK3 expression in metastasis to liver and lymph nodes. Microarray data in (C) was grouped based on relative level ofGRK3 expression (low, medium, and
high). (D) TCGA database was used to compare CXCR4 andGRK expression levels between normal breast tissue and tumor tissue, as in (A). (E) TCGA
database was used to determine changes in CXCR4,GRK3, andGRK5 expression levels in human breast cancer subtypes as in (B). Statistical significance
determined by Students t-test (A,D), ANOVA (B,E), and Log-Rank test (C).
doi:10.1371/journal.pone.0152856.g001
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confirmed by Western Blot (S2 Fig). Though both control and GRK3-overexpressing
MDA-MB-231 cells migrated significantly toward CXCL12, chemotaxis toward CXCL12 was
significantly inhibited by GRK3 over expression compared to control transfected cells (Fig 3A).
Given that metastasis is a multistep process that involves not only migration, but also invasion,
we compared control and GRK3-overexpressing MDA-MB-231 invasion through matrix.
GRK3-overexpressing MDA-MB-231 cells exhibited significantly less invasion compared to
controls (Fig 3B).
GRKs negatively regulates GPCR signaling by phosphorylation of terminal serine/threonine
residues leading to receptor desensitization and internalization [11, 16, 17]. To confirm that
overexpression of GRK3 was altering CXCL12/CXCR4 responses that culminated in increased
internalization and removal of CXCR4 from the cell surface, MDA-MB-231 cells with overex-
pressed GRK3 were compared to controls and had significantly more internalization of CXCR4
receptor in response to CXCL12 over time (Fig 4A).
Fig 2. CXCR4:GRK3 ratio correlates with the invasiveness of human breast cancer lines.Human breast cancer lines were analyzed by quantitative
real time PCR to determine the mRNA expression levels ofGRK3 andCXCR4. Transcript copy number was determined using the standard curve method.
Data shown are the average of two to four independent experiments. Error bars represent the SEM.
doi:10.1371/journal.pone.0152856.g002
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GPCR internalization following GRK phosphorylation is mediated by beta-arrestins [12,
36, 37].
To show how GRK3 can influence CXCR4 internalization by recruiting β-arrestin, we used
the TANGO assay as described in the Materials and Methods. Fig 4B shows the CXCL12 con-
centration-dependent internalization of CXCR4 (black open triangles), which is significantly
enhanced by the addition of GRK3 (blue closed circles). Known CXCR4 inhibitors AMD3100
(Fig 4C) and MSX-122 (Fig 4D) inhibit CXCL12-mediated arrestin recruitment in a concentra-
tion-dependent manner. By comparison, the cancer-relevant receptor CXCR3, which has been
shown to have functional interactions with CXCR4 [38–40], recruits β-arrestin in the TANGO
assay when stimulated with its ligand CXCL11, but the response is not enhanced by GRK3
(S5A Fig). CXCL12 stimulation of CXCR3 does not recruit β-arrestin, as expected (S5B Fig).
In contrast to MDA-MB-231, MDA-MB-468 are weakly-metastatic TNBC cells with a low
CXCR4:GRK3 expression ratio (Fig 2), suggesting that GRK3 may be mitigating migration and
Fig 3. Alterations in GRK3 affect migratory responses of human breast cancer lines to CXCL12.GRK3
expression was altered by overexpression or shRNA silencing in human breast cancer lines. (A) Chemotaxis
toward media or 50 nM CXCL12 of MDA-MB-231 transiently transfected with GRK3 or control plasmid was
assessed by a real-time modified Transwell assay. Transfection efficiency was routinely 40%. Results shown
are the mean of 5 independent experiments. (B) MDA-MB-231 invasion through Matrigel was analyzed after
24 hours and staining with Calcien-AM. The chemoinvasion index is defined as the ratio of relative
fluorescence of cells migrated toward CXCL12 over media control. Results shown are the mean of 3
independent experiments. (C) Chemotaxis toward media or 500nM CXCL12 of stably transduced MDA-MB-
468 cells was assessed by a real-time modified Transwell assay. Results shown are the mean of 4
independent experiments. (D) MDA-MB-468 invasion through Matrigel was analyzed using a 96-well invasion
assay. Results shown are the mean of 3 independent experiments. Error bars for all data represent the SEM.
Statistical significance determined by analysis of covariance (ANCOVA) linear regression model (A and C) or
by a two-tailed t-test (B and D): * p < 0.05; ** p < 0.01; *** p < 0.001; N.S. not significant.
doi:10.1371/journal.pone.0152856.g003
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invasion through increased desensitization/internalization of CXCL12-activated CXCR4. To
test this hypothesis, GRK3 was stably knocked down by lentiviral shRNA expression in
MDA-MB-468 cells and confirmed by Western Blot (S2 Fig). Control MDA-MB-468 cells did
not show statistically significant migration toward CXCL12. GRK3 knockdown in MDA-MB-
468 cells significantly increased in vitro chemotaxis (Fig 3C) and chemoinvasion (Fig 3D)
toward CXCL12, thereby making their migratory phenotype more analogous to the aggressive
MDA-MB-231 line. Taken together, the results indicate an important role for GRK3 in the
Fig 4. GRK3 regulates CXCL12-specific CXCR4 internalization and β-arrestin recruitment. (A) Control cells (empty plasmid) and GRK3-overexpressed
MDA-MB-231 cells were treated for the indicated times with 100 nM CXCL12 at 37°C. Surface expression of CXCR4 on the surface of cells was determined
by flow cytometry. Data shown are the mean of three experiments normalized to the zero time point. Error bars represent SEM. Statistical analysis was
performed using a two-tailed t-test. **p < 0.01. (B) Using a TANGO arrestin-recruitment assay, HTLA cells were transfected with either CXCR4 alone or
CXCR4 plus GRK3 as detailed in the Materials and Methods. Cells were plated in a 384 well plate and stimulated with CXCL12 at the indicated Molar
concentrations. Luminescence was measured 24 hours post-stimulation. Error bars represent +/- SEM (n = 3). (C) TANGO results testing the CXCR4
antagonist AMD-3100. As in (B), HTLA cells were transfected with CXCR4 and GRK3 plasmids and stimulated with 10−7 M CXCL12 (one concentration point
above EC50) following pre-treatment with AMD3100 at the indicated Molar concentrations. (D) TANGO results testing the CXCR4 antagonist MSX-122.
HTLA cells were transfected with CXCR4 and GRK3 plasmids and stimulated with 10−7 M CXCL12 following pre-treatment with MSX-122 at the indicated
Molar concentrations.
doi:10.1371/journal.pone.0152856.g004
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regulation of CXCL12/CXCR4-mediated functions and in the migratory phenotypes of human
TNBC cell lines.
3.3. GRK3 gene silencing potentiates mammary tumor establishment
and metastasis in vivo
To assess the role of GRK3 in metastasis in vivo, a syngeneic, immunocompetent mouse model
of TNBC [21] was used. The mouse mammary tumor line 66cl4-luc is a weakly-metastatic,
BALB/c tumor line expressing a luciferase construct that allows for tracking by in vivo optical
imaging [24]. GRK3mRNA and protein levels were silenced in the 66cl4-luc line by lentiviral
shRNA transduction (S1 Fig) in an analogous fashion to silencing GRK3 in the non-invasive
human MDA-MB-468 cells. Non-targeted control and GRK3-deficient 66cl4-luc cells were
surgically implanted into the mammary fat pads of BALB/c mice and monitored by optical
imaging for tumor growth and metastasis for six weeks, and organ-specific metastatic tumor
burden was examined in detail by histopathology at experiment termination. Non-target con-
trol 66cl4-luc cells established primary tumors in vivo, but extended few metastases (Fig 5A
and Table 1). In contrast, mice implanted with 66cl4-luc GRK3-deficient cells developed large
primary tumors and distant metastases (Fig 5B and Table 1). Fluorescent intensity was ana-
lyzed with Xenogen software and reported as average radiance (p/s/cm2/sr) to quantify primary
and metastatic tumor burden over time. The analysis determined that primary tumor burden
was not significantly different, albeit slightly increased on average, in GRK3-deficient tumors
compared to controls throughout the 6-week period (Fig 5C). More notably, mice implanted
with 66cl4-luc GRK3-deficient cells developed significantly more metastases at experiment ter-
mination (Table 1 and Fig 5D). Histological data confirmed GRK3-deficient 66cl4 cells metas-
tasized mostly to the lung, consistent with the model [28], and additionally to distant organ
sites, such as liver, at a higher frequency (Table 1). Along with the optical imaging data, nec-
ropsy of primary tumors showed that GRK3-deficient tumors displayed a different anatomy
(Fig 5E), suggesting that these tumors may appear larger due to cell movement and resemble
an invasive phenotype [41]. These in vivo data suggest that the metastasis of TNBC cells can be
altered when the negative signaling regulator GRK3 is affected and that the sites of metastasis
correlate with human data (Fig 1) as well as where CXCL12 is expressed.[7–9]
3.4. Silencing GRK3 expression does not alter cell proliferation, CXCL12
secretion, or anoikis
GRK3-deficient 66cl4-luc tumors appear larger in diameter than control tumors when visual-
ized by optical imaging and necropsy (Fig 5), and studies by Woerner and colleagues have
described an important role for GRK3 in regulating primary tumor growth in glioblastoma
[14]. Since growth rates could impact metastatic potential in breast cancer, an in vitro assay
was performed to assess intrinsic proliferation rates of GRK3-deficient and control 66cl4-luc
cells. No significant difference was found in the proliferation of these 66cl4-luc cells in in
vitro cultures at baseline (Fig 6A) or in the presence of ligand CXCL12 or CXCR4-antagonist,
AMD3100 (S6 Fig).
Autocrine stimulation from secreted CXCL12 has been shown to influence tumor behavior
and phenotype [42], and CXCL12 expression in breast cancer cells has been correlated with
decreased metastatic potential in humans [43]. To examine CXCL12 secretion from control
and GRK3 deficient 66cl4-luc cells, CXCL12 in supernatants was measured by ELISA but was
not found to be different between cell types (Fig 6B).
Epithelial cells, including normal breast epithelium, are dependent upon contact with
underlying extracellular matrix for survival and undergo apoptosis in response to detachment,
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a process termed anoikis. Resistance to anoikis is a hallmark of metastatic progression in cancer
[44]. Given that CXCR4 signaling is known to regulate anoikis in tumor progression [44, 45],
66cl4-luc GRK3-deficient cells were compared to 66cl4-luc control cells for their apoptotic
response to detachment; data showed that there was no intrinsic difference in anoikis between
the different 66cl4-luc tumor types in vitro (Fig 6C).
3.5. GRK3 deficiency increases migration of 66cl4-luc mammary tumor
cells to CXCL12
The analysis of human breast cancer cell lines in Figs 2 and 3 suggests that cells with higher
CXCR4:GRK3 ratios are more metastatic because of increased migration and invasion toward
CXCL12. Additionally, the in vivo 66cl4-luc model shows increased distant metastasis of
tumors to sites known to express high CXCL12 [7–9] after GRK3 silencing by lentiviral shRNA
(Fig 5 and Table 1). To determine whether GRK3-deficient 66cl4-luc metastasis could result
from enhanced CXCL12/CXCR4-mediated migration, a kinetic chemotaxis assay was per-
formed as previously described. Control 66cl4-luc cells did not migrate to CXCL12 over media
Fig 5. Increasing theCXCR4:GRK3 ratio in 66cl4-luc mammary tumor cells increases in vivometastasis. (A) Balb-c mice with 66cl4-luc control
transduced cells visualized by optical imaging at 6 weeks post-implantation demonstrate only primary tumor growth in contrast to mice with 66cl4-luc GRK3
deficient cells (B), which show extensive and distant metastasis. Images shown in C. and D. are representative of two independent experiments.
Quantification of total (C) and metastatic (D) tumor in control versus GRK3-deficient tumors as imaged by luciferase activity. Data shown in (C) are n = 10
mice at weeks 0 and 2, n = 9 week 4, n = 7 week 6 (due to disease mortality). Data in (D) are n = 8 for Control, n = 7 for GRK3-deficient. (E) Necropsy of Balb-
c mouse with control 66cl4-luc tumor cell implant showing small, encapsulated primary tumor (left panel). Necropsy of animal with GRK3-silenced 66cl4-luc
tumor cell implant demonstrating larger, friable primary tumor and prominent neovascularization (right panel). All error bars represent SEM.
doi:10.1371/journal.pone.0152856.g005
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alone, while GRK3-deficient 66cl4-luc cells showed significantly enhanced directional migra-
tion to CXCL12 (Fig 7A). Because 66cl4 cells are thought to perform poorly in standard in
vitro invasion assays similar to those used for human cells in Fig 3 [28], a Cultrex 96-well
tumor invasion plate was coated with a lower concentration basement membrane extract (0.2X
BME) to assess in vitro invasion. While detectable amounts of cells invaded the Matrigel, addi-
tion of CXCL12 did not significantly increase the invasiveness of either control cells or GRK3
deficient 66cl4-luc cells over media alone (Fig 7B). Because breast cancer cells can have differ-
ent behaviors and phenotypes in 3-dimensions versus 2-dimensions, 66cl4-luc cells were also
tested in a 3D system of invasion (S7 Fig) with negative results similar to the 2D Transwell
invasion assay.
4. Discussion
Breast cancer metastasis is known to be mediated in part by the CXCL12/CXCR4 signaling axis
[7]. We now add G protein coupled receptor kinase 3 (GRK3) as an important regulator,
Table 1. GRK3-deficient 66cl4-luc mammary tumors disseminate distant metastasis.
Primary
Tumor
Liver
Metastasis
Lung
Metastasis
Spleen
Metastasis
Adrenal/Kidney
Metastasis
Pancreas
Metastasis
Skeletal Muscle
Metastasis
GRK3 kd X X
GRK3 kd X X
GRK3 kd X X X X
GRK3 kd X
GRK3 kd X X X X X
GRK3 kd X X X
Control
Control X X
Control
Control X
Control
Control X X X
Control
doi:10.1371/journal.pone.0152856.t001
Fig 6. GRK3 deficient and control 66cl4-luc cells secrete soluble CXCL12, proliferate, and undergo apoptosis similarly. (A) Viable cell density was
measured by colormetric assay (Cell Counting Kit-8, Dojindo) at indicated times and cell number estimated by standard curve (n = 3 + SEM). (B) Cells were
plated in triplicate at the indicated number per well and incubated in culture conditions for 48 hours. CXCL12 levels in the supernatants were determined by
sandwich ELISA and quantified by standard curve (n = 3; mean + SEM). (C) GRK3-deficient and control 66cl4-luc cells were incubated in adherent versus
detached (poly-HEMA) conditions overnight and analyzed for apoptosis by flow cytometry for Annexin V and propidium iodide staining. Data is the mean of 4
independent experiments (error bars = SEM).
doi:10.1371/journal.pone.0152856.g006
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specifically with respect to invasion and metastasis, in human breast cancer tissue, TNBC cell
lines, and in an immunocompetent mouse model. Previous work by others has suggested that
quantitative levels of CXCR4 surface expression, as well as CXCL12 concentration and avail-
ability, can affect the metastatic phenotype [9]. Recent evidence points to an even greater
importance for CXCR4 expression in TNBC, which contributes to tumor size and metastatic
potential as well as predicts poor prognosis in terms of overall and disease-free survival [46–
48]. However, further experiments have clarified that the magnitude of CXCR4 signaling, as
perturbed by gene silencing, mutation, overexpression, or antagonism, is a key factor that
affects increased migration, invasion, and metastasis [7–9, 30, 49]. In support of this argu-
ment, Holland et al. showed that the absolute level of CXCR4 expressed on the surface of
breast cancer cells alone did not accurately reflect or predict metastatic potential [10]. The
data we present offers a mechanistic explanation for the role of CXCR4 signaling in breast
cancer metastasis. The data show that relative GRK3 expression correlates with tumorgenicity,
invasiveness, and metastatic potential in both human (Figs 1, 2 and 3) and mouse models (Fig
5 and Table 1) and further, that manipulating GRK3 levels directly affects the chemotactic
and metastatic potential of breast cancer cells (Figs 3 and 7). Thus, we propose that high
CXCR4 on the cell surface, combined with decreased intracellular regulatory GRK3, leads to
impaired receptor internalization and more active CXCL12-mediated migration of the cancer
cell (Fig 8).
We acknowledge that GRK3 in breast cancer is unlikely to be affecting CXCL12/CXCR4
interactions exclusively in vivo and could certainly be affecting additional chemokine receptors
such as CXCR7 [50–52], CXCR3 [53, 54], CCR7 [55–57], and others.[58] However, our data
support a strong role for GRK3-mediated regulation of CXCL12 metastatic responses, arrestin-
mediated recruitment, and CXCR4 receptor internalization in vitro (Figs 3, 4 and 7). In con-
trast, there is less compelling data for GRK3-mediated regulation of CXCR3 where we show
that arrestin recruitment is independent (S5 Fig), and there was a lack of correlational expres-
sion data supporting CXCR7:GRK3 to the metastatic phenotype (S4 Fig). As genotyping has
become an important tool to provide the prognosis and treatment of TNBC [59], the relative
Fig 7. GRK3-deficient 66cl4-lucmammary tumor cells have increased chemotaxis but not invasion.GRK3 was silenced by lentiviral shRNA in
66cl4-luc cells to examine the effect on migration. 100,000 cells were added per well to the top of a 96-well Fluoroblok Transwell plate, and 12.5nM (100ng/
ml) CXCL12 or media was in the lower chamber. Migration was monitored over 4 hours using a Fluoroskan Ascent FL plate reader. (A) Control transduced
66cl4-luc cells do not migrate toward CXCL12 (closed circle) over media control (open square) whereas GRK3 deficient 66cl4-luc cells display directional
chemotaxis toward CXCL12 (closed triangle) over media control (open diamond). Statistics significance determined by analysis of covariance (ANCOVA)
linear regression model: *** p < 0.001; N.S. not significant. (B) Control and GRK3 deficient 66cl4-luc cells were loaded into the upper chamber of Cultrex
invasion plates in triplicate (see Materials and Methods). After addition of media alone or CXCL12 (50 or 100 nM) to the lower chamber, cells were incubated
for 24 hours, stained with Calcein, and then counted for invasion into matrix (n = 3 ± SEM).
doi:10.1371/journal.pone.0152856.g007
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Fig 8. Summary model of GRK3 regulation of CXCR4-driven metastasis. Extracellular ligand stimulation of CXCL12 on G protein-coupled receptor
(GPCR) CXCR4 elicits conformational changes of receptor, activation and dissociation of guanine nucleotide binding proteins, and downstream signaling for
tumor cell migration (A). Negative regulation of surface receptor expression is mediated by G protein-coupled receptor kinase 3 (GRK3), which
phosphorylates the carboxyl terminus of CXCR4 for desensitization, thus prompting β-arrestin recruitment for receptor internalization. The presence of GRK3
limits ligand/receptor signaling by contributing to desensitization and by reducing CXCR4 surface expression (A, inset). Upon GRK3 deficiency, CXCR4
receptor expression is enhanced thus allowing increased opportunities for CXCL12 extracellular ligand/receptor stimulation, signaling, and migration (B). The
absence of GRK3 enhances ligand/receptor signaling by prolonging CXCR4 surface expression (B, inset).
doi:10.1371/journal.pone.0152856.g008
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gene expression of markers such CXCR4 and GRK3may provide additional prognostic infor-
mation as it pertains specifically metastasis.
The metastatic potential of breast cancer cells is acutely sensitive to regulation of the
CXCL12/CXCR4 signaling axis governed by receptor expression, desensitization, internaliza-
tion, and recycling dynamics [9, 18, 19]. These properties of CXCR4 are directly influenced by
phosphorylation by GRKs and subsequent downstream components, such as β-arrestins [16,
17]. GRK3 has previously been shown to regulate tumor growth and proliferation in glioblas-
toma (GBM). GRK3 expression is down-regulated by EGFR signaling in GBM compared to
normal astrocytes, which leads to a corresponding increase in tumor growth.[14] Published
data by others have also shown that down-regulation of GRK6 in medulloblastoma [15] and
Lewis lung carcinoma [60] can similarly regulate tumor size, migration, and metastasis. In con-
trast, our results correlate GRK3 with breast cancer metastatic potential via regulation of
tumor cell migration and invasion (Figs 3 and 7) without significant effect on tumor growth or
detachment-induced death (Fig 6). These differences could potentially be explained by differ-
ent cell types having altered GRK-specific phenotypes or redundancy based on tissue expres-
sion and/or targeted GPCR-mediated regulation.
In vivo bioluminescent imaging of 66cl4-luciferase tumors demonstrates an apparently
larger, more diffuse tumor arising from GRK3-knockdown cells (Fig 5) despite similarity of cel-
lular radiance quantification. One potential explanation is that the density of the tumor might
be affected by the mobility of the individual GRK3-deficient tumor cells or by the recruitment
of non-tumor cells into the tumor site. GRK3-deficient tumors also contained notable areas of
necrotic tissue (data not shown). Since necrotic cells would no longer luminesce, it is also possi-
ble that GRK3-deficient tumors did proliferate more in vivo in response to environmental cues
not present in the in vitro assay, and that resultant tissue necrosis confounded optical quantifi-
cation. The appearance of necrotic regions in primary tumors can also contribute to increased
metastases [61, 62]; however, this hypothesis was not directly tested in this study and remains a
future endeavor.
High levels of CXCL12 known to exist in metastatic target tissues [7] raise the possibility
that the functional outcome of altered GRK3 expression occurs distally from the primary
tumor. Since 66cl4-luc cells are weakly invasive and this phenotype is unaltered by GRK3 gene
silencing (Fig 7B), we propose that the observation of increased metastases of GRK3-deficient
66cl4-luc cells is due to increased migration (Fig 7A), possibly within the tumor microenviron-
ment, leading to higher rates of intravasation that are controlled by other mechanisms. This
interpretation is consistent with the larger, diffuse tumors imaged in mice implanted with
66cl4-luc GRK3-deficient cells (Fig 5). The sprawling, less dense tumor mass and increased
chemotactic ability of the GRK3-deficient 66cl4-luc cells suggest that more motile cells within
the primary tumor ultimately result in the increased distant metastases. However, our human
cell line data do show an invasive phenotype, thus the findings using the 66cl4-luc cell line may
be species and/or tumor specific. Future studies examining the in vivo and in vitromigratory,
invasive, and metastatic potential of human derived breast cancer cells will be needed to see if
these present results are generalizable to a broader array of malignant phenotypes.
CXCL12 binds to CXCR7 as well as CXCR4 [34]. CXCR7 is a dual-specificity GPCR that
binds to CXCL12 with higher affinity than CXCR4 and also binds to the CXCR3 ligand,
CXCL11, with low affinity. CXCR7 may function as a regulator of CXCR4 signaling by hetero-
dimerization or as a decoy receptor, scavenging CXCL12 without leading to traditional G pro-
tein signals [63]. In addition, CXCR7 is thought to have G protein independent signaling
functions through beta-arrestin mediated signals [39, 64]. CXCR7 in breast cancer cells can
affect tumor growth, survival, and adhesion to vasculature [65]. Furthermore, CXCR7 can also
influence CXCR4-mediated chemotaxis and invasion, as well as independently regulate tumor
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growth by promoting angiogenesis [34]. The breast cancer cells used in the current study failed
to demonstrate a correlation between CXCR7 levels and tumor cell migration or metastatic
potential (S4 Fig). This may be due to low levels of CXCR7 expression in these cells. Further-
more, current data implicate GRK2, not GRK3, as a potential regulator of arrestin-biased sig-
naling through CXCR7, which fails to activate classic G protein pathways [64, 66, 67]. These
authors acknowledge that GRK3 likely regulates other GPCRs that have relevance to cancer
[14, 68, 69]; in agreement with their speculation, the data presented herein describe an impor-
tant functional role for GRK3 in regulating CXCR4 that impacts metastatic breast cancer
progression.
Most TNBC is associated with high CXCR4 expression, increased metastatic potential, and
poor patient prognosis [47, 48]. Our data emphasize the functional relationship of GRK3 as it
pertains to CXCL12/CXCR4 migration in breast cancer and specific molecular subtypes. The
analysis of human genetic data confirms potential involvement of GRK3 in tumor progression
and metastasis (Fig 1). Across large datasets, decreased GRK3 expression correlated better with
tumor (vs normal breast) than changes in CXCR4 expression. In our resected mouse mammary
tumors, the CXCR4:GRK3 expression ratio was stable even after 6 weeks of tumor implantation
and distant metastasis (S2 Fig), suggesting that the CXCR4:GRK3 ratio is preserved and could
be a useful prognostic indicator at extended times during the disease course. Others have
proposed CXCR4 signaling and regulatory pathways as an attractive target for breast cancer
treatment [8, 10, 48, 70]. Considering the importance of GRK3 regulation of breast cancer
migration, invasion, and metastasis described in this manuscript, understanding which tumors
have more dysregulated signaling through CXCL12/CXCR4 could be used as a biomarker to
predict which patients might respond better to CXCR4 antagonism or as an alternative, tar-
geted therapy directed specifically at GRKs.
Supporting Information
S1 Fig. Altering the CXCR4:GRK3 in 66cl4-luc mammary tumor cells by GRK3 shRNA
silencing. (A) 66cl4-luc murine mammary tumor cells were stably transduced with lentiviral
GRK3 shRNA or non-target control plasmids and were analyzed by qRT-PCR to determine
the mRNA expression levels of GRK3 and CXCR4 after normalization to the IDUA housekeep-
ing gene. Data is expressed as a ratio of CXCR4 to GRK3. 66cl4-luc Control n = 3, 66cl4-luc
GRK3-deficient n = 4. (B) Representative GRK3Western blot showing shRNA silenced
GRK3-deficient 66cl4-luc cells compared to controls after immunoprecipitation. Blots were
stripped and reprobed to confirm equal loading. Shown is actin blot of IP supernatant lanes.
(C) Prior to implantation into Balb/c mice for in vivo studies, GRK3 is silenced approximately
50–60% in 66cl4-luc cells versus control as determined by qRT-PCR (n = 4). (D) GRK3 gene
silencing was validated at 6 week experiment termination by qRT-PCT (n = 4). GRK3 mRNA
expression was normalized to IDUA housekeeping gene and relative % expression determined
by ΔΔCT method. All error bars represent SEM.
(TIF)
S2 Fig. Altered GRK3 protein expression in human breast carcinoma lines. (A) Western
blot depicts GRK3 protein overexpression in MDA-MB-231 cells; lysates were also blotted for
actin as a loading control. (B) GRK3Western blot of MDA-MB-468 cell lysates that were stably
transduced with lentiviral non-target control plasmid (NT) or GRK3 shRNA (GRK3 silenced).
Lysates of equal protein concentration (determined by Protein BCA assay) were immunopre-
cipitated using anti-human GRK3 monoclonal antibody (Abgent). Immunoprecipitation
samples, top, show GRK3 protein knockdown in the shRNA-silenced MDA-MB-468 cells.
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GADPH in IP supernatants, bottom, confirm equal loading.
(TIF)
S3 Fig. Surface receptor expression is not altered following stable GRK3 shRNA knockdown.
Human breast cancer line MDA-MB-468 (A, C) and murine breast cancer line 66cl4-luc (B, D)
that have been stably transduced with GRK3 shRNA (red) or a control sequence (blue) and
were stained for CXCR4 and CXCR3 and analyzed by flow cytometry. For human cells, antibod-
ies used were: mouse anti-human CXCR4-PE (clone 12g5, isotype mouse 2a PE, Biolegend),
anti-human CXCR3-APC (clone 49801, isotype mouse G1 APC, R&D Systems), and for mouse
cells, rat anti-mouse CXCR4-PE (clone 2b11, isotype rat 2b PE, eBioscience) and rat anti-mouse
CXCR3-APC (clone 220803, isotype rat 2a, R&D Systems). Negative controls were stained
using equivalent amounts of isotype color controls. Shown are representative histograms of 3
independent experiments.
(TIF)
S4 Fig. CXCR7:GRK3 relative copy number does not correlate with the metastatic potential
of human breast cancer lines.Human breast cancer lines (in descending order moving from
left to right of most highly metastatic to least metastatic) were analyzed by quantitative real
time PCR to determine the mRNA expression levels of GRK3 and CXCR7. Transcript copy
number was determined using the standard curve method. Data shown are the average of two
to four independent experiments. Error bars represent the SEM.
(TIF)
S5 Fig. CXCR3 recruits arrestin independently of GRK3 in response to CXCL11 and does
not recruit arrestin in response to CXCL12. (A) Using a TANGO arrestin-recruitment assay,
HTLA cells were transfected with either CXCR3 alone or CXCR3 plus GRK3 as detailed in the
Materials and Methods. Cells were plated in a 384 well plate and stimulated with CXCL11 at
the indicated Molar concentrations. Luminescence was measured 24 hours post-stimulation.
Error bars represent +/- SEM (n = 3). (B) HTLA cells were transfected with either CXCR3
alone or CXCR3 plus GRK3 as in (A). Cells were plated in a 384 well plate and stimulated with
CXCL12 at the indicated Molar concentrations. Luminescence was measured 24 hours post-
stimulation. Error bars represtent +/- SEM (n = 3).
(TIF)
S6 Fig. Addition of CXCL12 or AMD3100 does not alter the proliferation of 66cl4-luc cells
over 72 hours. Viable cell density was measured by colormetric assay (Cell Counting Kit-8,
Dojindo) at indicated times and cell number estimated by standard curve (n = 2 + SEM).
66cl4-luc non-target control (A) and GRK3-silenced (B) cell proliferation was tested with or
without exogenous CXCL12 (100 ng/ml) added to the culture media. Since 66cl4-luc cells
make large amounts of endogenous CXCL12 (Fig 6), 66cl4-luc non-target control (C) and
GRK3-silenced (D) cell proliferation was also tested in presence or absence of CXCR4 antago-
nist AMD3100 (5 μg/ml).
(TIF)
S7 Fig. 66cl4-luc cells do not invade in a 3D invasion assay regardless of CXCL12 stimula-
tion or GRK3 deficiency. 66cl4-luc murine breast cancer cells were tested using the Cultrex
3D Spheroid Cell Invasion Assay (Trevigen) according to manufacturer’s suggestions. Briefly,
cells were allowed to assemble into spheroids for 3 days. Invasion matrix and media (+/-
CXCL12) were added and images captured (invasion Day 0). Images were captured at the days
indicated and analyzed using Image J software as described in the product insert. Data shown
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is the mean of two independent experiments (error bars +/- SEM).
(TIF)
S1 Methods. Supplemental Information.
(DOCX)
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